Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

@article{Tyrrell2006TolerabilityEA,
  title={Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration},
  author={Chris J. Tyrrell and Peter Iversen and Teuvo L.J. Tammela and John Anderson and Thomas Bj{\"o}rk and Amir V. Kaisary and Thomas W. Morris},
  journal={BJU International},
  year={2006},
  volume={98}
}
To evaluate the pharmacokinetics, tolerability and effect on endocrinology of bicalutamide given as once‐daily monotherapy at doses of >150 mg to patients with locally advanced (M0) or metastatic (M1) prostate cancer, with efficacy as a secondary endpoint. 
Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor‐axis in castration‐resistant prostate tumors
TLDR
It is hypothesize that pharmacological targeting of the AR‐axis by combination treatment with bicalutamide plus carbidopa significantly enhances antitumoral activity in vitro and in vivo compared to monotherapy with either drug. Expand
Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study.
TLDR
The findings suggest that enzalutamide monotherapy in men with hormone-naive prostate cancer of varying severity provides a level of disease suppression, and was generally well tolerated. Expand
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
TLDR
Long-term enzalutamide monotherapy in men with noncastrate HNPC is associated with large sustained reductions in PSA, signals indicating a favorable tumor response, and favorable safety/tolerability profile, with relatively small negative effects on total-body BMD. Expand
Safety of antiandrogen therapy for treating prostate cancer
TLDR
This review elucidates the safety profile of antiandrogens, in particular focusing on the tolerability profile of each drug either when employed in combination with castration or as monotherapy, in hormone-naive or in castration-resistant patients. Expand
Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
TLDR
The failure to discover new AR antagonists has occurred in the face of continued research; to enable progress, a clear understanding of the reasons for failure is required. Expand
Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
TLDR
Serum testosterone could play an important role when delayed maximal androgen blockade is indicated as the second-line treatment in patients with castration-resistant prostate cancer, and might be more beneficial in Patients with a serum testosterone level of ≥ 5ng/dl. Expand
Long Term Progression-Free Survival in a Patient with Locally Advanced Prostate Cancer under Low Dose Intermittent Androgen Deprivation Therapy with Bicalutamide Only
TLDR
A 60-year-old patient, initially presenting with a PSA elevation of 19.2 ng/mL in 1996, is reported, who underwent an open radical prostatectomy and adenocarcinoma of the prostate, classified as pT3a, pR1, pV0, and pL1 in 2001. Expand
Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks.
TLDR
ADT is associated with an increased risk of multiple side effects that may reduce quality of life and/or OS, so ADT should be used with knowledge of its potential long-term side effects and with possible lifestyle interventions, especially in settings with the highest risk-benefit ratio. Expand
Androgen Deprivation Therapy for Prostate Cancer.
  • V. Pagliarulo
  • Medicine, Biology
  • Advances in experimental medicine and biology
  • 2018
TLDR
Different hormonal compounds available for the treatment of PC are compared, both from a pharmacological standpoint, and in terms of contemporary clinical indications. Expand
Contemporary role of androgen deprivation therapy for prostate cancer.
TLDR
It is suggested that in men with nonmetastatic disease, the use of primary ADT as monotherapy has not shown a benefit and is not recommended, while ADT combined with conventional-dose RT for patients with high-risk disease may delay progression and prolong survival. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 20 REFERENCES
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
TLDR
To evaluate, in the ongoing EPC trial programme, the efficacy and tolerability of bicalutamide 150 mg once daily in addition to standard care for localized or locally advanced, nonmetastatic prostate cancer. Expand
CasodexTM 10–200 mg Daily, Used as Monotherapy for the Treatment of Patients with Advanced Prostate Cancer
TLDR
The intrinsic efficacy of Casodex was demonstrated despite increases of 60% in testosterone levels, however, this increase reached a plateau after 4–12 weeks of therapy, but the majority of values remained within the normal range. Expand
Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group.
TLDR
The results show that Casodex 50 mg is effective and well tolerated in the treatment of advanced prostate cancer. Expand
A Randomised Comparison of ‘Casodex’TM (Bicalutamide) 150 mg Monotherapy versus Castration in the Treatment of Metastatic and Locally Advanced Prostate Cancer
TLDR
‘Casodex’ 150 mg monotherapy is an option for patients with M1 prostate cancer for whom surgical or medical castration is not indicated or is not acceptable and has an acceptable tolerability profile. Expand
Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program.
PURPOSE We determine the efficacy and tolerability of bicalutamide as immediate therapy, either alone or as adjuvant to treatment of curative intent, in patients with clinically localized or locallyExpand
Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years.
TLDR
Bicalutamide 150-mg monotherapy provides a similar survival outcome to castration in previously untreated patients with nonmetastatic advanced prostate cancer and confers statistically significant benefits over castration with respect to sexual interest and physical capacity. Expand
Side effects of endocrine treatment and their mechanisms: Castration, antiandrogens, and estrogens
TLDR
This paper is a survey of the most important early side effects of the different modes of endocrine treatment, their etiology, and possible ways to avoid or treat them. Expand
Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer?
TLDR
Patients with a higher disease burden (PSA >400 ng/ml) may decide that quality of life and symptomatic benefits outweigh the slight survival disadvantage seen in clinical trials and opt for bicalutamide monotherapy as an alternative to castration. Expand
Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.
PURPOSE Nonsteroidal antiandrogen monotherapy may be a treatment option for some patients with advanced prostate cancer. We report a survival and safety update from an analysis of 2 studies in whichExpand
Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma.
TLDR
A multicentre, randomised trial in the United Kingdom and the Republic of Ireland, in which the LHRH analogue Zoladex, administered subcutaneously every 28 days, was compared with orchiectomy found both treatments were equally effective in lowering serum testosterone concentrations to within the surgically castrate range. Expand
...
1
2
...